- LexaGene Holdings Inc. (LXG) has sold a MiQLab System to Meridian Veterinary Capital LLC
- Meridian purchased a MiQLab to reduce the turnaround time for diagnostic testing so that their veterinary partners can make evidence-based medical care decisions soon after seeing a sick pet
- MiQLab is an easy-to-use microbial detection system that provides fast, accurate, and reliable detection of up to 27 pathogens and antimicrobial resistance markers at once
- LexaGene is a molecular diagnostics company that develops molecular diagnostic systems
- LexaGene Holdings Inc. (LXG) is up 2.63 per cent on the day, trading at $0.78 per share
LexaGene Holdings Inc. (LXG) has sold a MiQLab System to Meridian Veterinary Capital LLC.
Meridian, a company that provides custom building solutions for animal health professionals, will deploy the MiQLab System for use in emergency and specialty veterinary hospitals across the country.
MiQLab is an easy-to-use microbial detection system that provides fast, accurate, and reliable detection of up to 27 pathogens and antimicrobial resistance markers at once.
Meridian purchased a MiQLab to reduce the turnaround time for diagnostic testing so that their veterinary partners can make evidence-based medical care decisions soon after seeing a sick pet.
“We’re thrilled to welcome Meridian to our customer portfolio,” remarked Dr. Jack Regan, founder and CEO of LexaGene.
“Time and time again, we hear from our early adopters that the MiQLab boosts the confidence veterinarians have in making an initial diagnosis and prescribing the right therapy for any detected pathogen.”
Meridian’s focus is on the advancement of pet healthcare. The company helps animal care providers design, build, and finance efficient, comfortable, and cost-effective care facilities that have state-of-the-art diagnostic and treatment capabilities.
“LexaGene’s MiQLab System is the start of a technology wave that is sweeping through veterinary care,” added Dr. Regan.
“We listened to our veterinary partners and developed the MiQLab System to help meet their point-of-care diagnostic needs.”
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers.
LexaGene Holdings Inc. (LXG) is up 2.63 per cent on the day, trading at $0.78 per share as of 10:37 am ET.
